CONTER Srl - Meklēšanas rezultāti

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

zostavax

merck sharp & dohme b.v. - vējbakas-zoster vīruss (dzīvs, novecojis) - herpes zoster; immunization - vīrusu vakcīnas - zostavax ir indicēts herpes zoster (zoster vai zoster) profilaksei un postherpētiskas neiralģijas izraisīšanai no herpes zoster. zostavax ir norādīts imunizācijas no personām 50 gadus veci vai vecāki.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

shingrix

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vakcīnas - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. izmantot shingrix būtu saskaņā ar oficiālās rekomendācijas.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

cuprymina

a.c.o.m. - advanced center oncology - vara (64cu) hlorīds - radionuklīdu attēlveidošana - citi diagnostiskie radiofarmaceitiskie līdzekļi - cuprymina ir radiofarmaceitiskais prekursors. tas nav paredzēts tiešai lietošanai pacientiem. Šīs zāles jāizmanto tikai pārvadātāja molekulu radioaktīvai iezīmēšanai, kuras ir speciāli izstrādātas un atļautas radioaktīvai marķēšanai ar šo radionuklīdu.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

jakavi

novartis europharm limited - ruksolitinibs (fosfāts) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiski līdzekļi - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi ir norādīts ārstēšanai pieaugušiem pacientiem ar polycythaemia vera, kas ir izturīgas pret vai nepanes hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

xeljanz

pfizer europe ma eeig - tofacitinibs - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 un 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.